BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2025.

The Dow Jones Industrial Average slid 821.91 points, or 1.66%, to close at 48,804.06. The S&P 500 dropped 1.04% to 6,837.75, while the Nasdaq Composite declined 1.13% to 22,627.27.

Multi-dose use introduces handling and safety considerations, including dose dialing accuracy and needle replacement, with downstream implications for adherence, dispensing workflows, and ...

One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.

A lot of casino products ask your phone to behave like a small cinema. They load a themed lobby, a soundtrack, a set of reels, a bonus map, and enough animation to heat a modest pocket. Aviator works ...

"At MacroGenics, our top priority is patient safety,” said Eric Risser, President and CEO. "MacroGenics is fully committed to ...

Wegovy generated DKK 79.1 billion in net revenues for Novo Nordisk in 2025, a 35.9% increase year-on-year. Learn why NVO stock is a strong buy.

A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer ...

Chittagong is grappling with a severe water crisis as production at four Chittagong Water Supply and Sewerage Authority (WASA) treatment plants has declined due to rising salinity in the Halda River ...

Fleet News first reported that Renault was intending to acquire a 100% stake in the business at the start of this month. The three have now signed a binding agreement today (Monday, February 23), ...

AMC26 seeks to mobilise global capital to invest in the continent in the face of geopolitical shifts wreaking havoc on ...

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, ...